Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : GSK
Deal Size : $546.0 million
Deal Type : Agreement
Rgenta & GSK Develop RNA Small Molecule Splice Modulators in Strategic Alliance
Details : Under the agreement, Rgenta will use its proprietary discovery platform to develop novel oral RNA-targeting small molecule splice modulators against multiple targets nominated by GSK for development.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $46.0 million
December 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : GSK
Deal Size : $546.0 million
Deal Type : Agreement
Rgenta Doses Patients in Trial For MYB-Targeting Drug in ACC And CRC
Details : RGT-61159 is an orally available small molecule designed to specifically modulate splicing of the transcription factor MYB. It is being evaluated for adenoid cystic carcinoma & colorectal cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 08, 2024
Rgenta Therapeutics Gets IND Clearance for RGT-61159 in ACC and CRC
Details : RGT-61159 is an orally available small molecule designed to specifically modulate splicing of the transcription factor MYB. It is being evaluated for adenoid cystic carcinoma & colorectal cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2024
Details : RGT-61159 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Adenoid Cystic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : H. Lundbeck AS
Deal Size : $110.0 million
Deal Type : Collaboration
Rgenta Therapeutics Enters into a Collaboration with Lundbeck
Details : Rgenta will use its novel and integrative discovery platform to identify and optimize RNA-targeting small molecules against high-value targets. Rgenta will grant Lundbeck license of candidate molecules, which will be developed and commercialized by Lundb...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $10.0 million
August 04, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : H. Lundbeck AS
Deal Size : $110.0 million
Deal Type : Collaboration